![]() |
市場調查報告書
商品編碼
2088739
CBD寵物市場:2026-2032年全球市場預測(依產品類型、寵物種類、成分、應用及通路分類)CBD Pet Market by Product Type, Pet Type, Source, Application, Distribution Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,CBD 寵物市場將成長至 1,016,090,000 美元,複合年成長率為 15.51%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 3.7024億美元 |
| 預計年份:2026年 | 4.1834億美元 |
| 預測年份 2032 | 1,016,090,000 美元 |
| 複合年成長率 (%) | 15.51% |
CBD寵物市場正從新興產品類別發展成為寵物健康經濟體系中受監管、以實證為基礎的細分市場。市場需求集中在以大麻為基礎的寵物產品上,例如CBD油、軟咀嚼片、外用膏和功能性犬用零食,旨在幫助寵物鎮靜、支持運動功能、呵護老年寵物並維持日常健康。推動這一市場成長的宏觀經濟因素與推動高階寵物護理的因素相同:寵物人性化、伴侶動物健康支出增加、D2C(直接面對消費者)業務的興起以及人們對植物來源健康成分日益成長的興趣。
寵物CBD市場最顯著的變化是從非正式的健康產品轉變為專業生產、品質有保證的寵物配方產品。寵物飼主越來越希望產品提供分析證書、透明的THC含量資訊、批次可追溯性以及清晰的劑量指導,而零售商則越來越不願意與那些做出未經證實的疾病治療聲明的品牌合作。這提高了寵物CBD公司之間的競爭門檻,推動了對符合GMP規範的生產、潔淨標示成分以及基於獸醫專業知識的產品研發的需求。
人工智慧 (AI) 正在成為 CBD 寵物市場中一項切實有效的差異化優勢,它能夠改善產品開發、客戶教育、供應鏈管理和合規性監控。 AI 驅動的分析可以識別消費者搜尋計劃,並最佳化 D2C(直接面對消費者)、電商平台和專業零售通路的履約。
北美仍然是CBD寵物產品商業性化程度最高的地區,其中美國主導,加拿大的聯邦大麻法律規範(FDA)對動物產品中CBD的監管仍然限制了其功效聲明的合法性。加拿大擁有更清晰的國家大麻管理體制,但獸醫取得CBD產品和產品核准流程仍受到嚴格控制。
在東協地區,由於部分成員國嚴格的毒品法律以及對大麻衍生消費品接受程度不一,CBD寵物產品的商業化仍受到限制。因此,合規進口、THC含量控制和消費者教育至關重要。海灣合作理事會(GCC)國家則較為保守。有意進入海灣市場的公司在開展寵物CBD產品業務之前,必須優先考慮法規實質審查、海關法規、獸藥產品法規以及某些司法管轄區的零容忍政策。
美國是推動寵物CBD產品需求的核心市場,但企業必須意識到,美國食品藥物管理局(FDA)尚未批准CBD作為動物飼料添加劑或寵物保健品成分。加拿大的大麻監管體系營造了系統化的環境,而隨著拉丁美洲大麻政策和獸醫保健管道的日益成熟,墨西哥和巴西也提供了長期的發展機會。在歐洲,英國、德國、法國、義大利和西班牙對高階寵物護理產品的需求強勁,但CBD寵物品牌必須遵守新食品法規、獸藥分類、各國THC含量限制以及特定國家的廣告標準。俄羅斯的情況更為複雜,涉及許多監管和地緣政治因素。
行業領導企業應優先考慮建立信任而非規模擴張。最具影響力的CBD寵物品牌會投資於第三方檢測、逐批次分析證書、THC和污染物控制、透明的工業大麻採購,以及基於動物體型的清晰劑量指導。在行銷方面,他們應避免聲稱產品具有治療疾病的功效,而是強調以高品質的文件和獸醫審核為支撐的、負責任的寵物健康理念。
本執行摘要基於對既定監管事實、已發布的政府指南、公認的大麻政策框架、寵物護理行業趨勢以及大麻基寵物健康領域實際商業實踐的系統性審查。主要參考資料包括美國2018年農業法案中關於大麻的框架、美國食品藥物管理局(FDA)關於CBD不被批准作為動物食品或寵物補充劑的觀點、加拿大的聯邦大麻法律規範以及歐盟對CBD的「新型食品」監管方法。
儘管CBD寵物市場具有長期發展潛力,但該領域的成功發展取決於信任、嚴格的監管和產品質量,而不是過度標語。寵物飼主對大麻基健康解決方案表現出濃厚的興趣,尤其關注犬類和老年寵物,但監管機構仍在密切關注CBD在動物口服產品中的應用。
The CBD Pet Market is projected to grow by USD 1,016.09 million at a CAGR of 15.51% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 370.24 million |
| Estimated Year [2026] | USD 418.34 million |
| Forecast Year [2032] | USD 1,016.09 million |
| CAGR (%) | 15.51% |
The CBD pet market is evolving from a novelty category into a regulated, evidence-sensitive segment of the broader pet wellness economy. Demand is concentrated in hemp-derived pet products such as CBD oil for dogs, soft chews, topical balms, and functional treats positioned around calm behavior, mobility support, aging pet care, and everyday wellness. Growth is being shaped by the same macro forces driving premium pet care: humanization of pets, higher spending on companion animal health, direct-to-consumer commerce, and rising interest in plant-derived wellness ingredients.
Regulatory clarity remains the defining constraint. In the United States, the 2018 Farm Bill removed hemp with no more than 0.3% delta-9 THC from the federal controlled substances list, but the U.S. FDA has not approved CBD for use in animal food, feed, or pet supplements. This creates a market where compliant labeling, third-party testing, contaminant control, transparent hemp sourcing, and conservative claims management are essential for credible CBD pet brands.
The most important shift in the CBD pet landscape is the movement from informal wellness products to professionally manufactured, quality-assured pet formulations. Pet owners increasingly expect certificates of analysis, THC transparency, batch traceability, and clear dosing guidance, while retailers are reducing exposure to brands that rely on unsubstantiated disease-treatment claims. This has raised the competitive bar for pet CBD companies and strengthened demand for GMP-aligned production, clean-label ingredients, and veterinarian-informed product development.
Channel dynamics are also changing. E-commerce and subscription models help brands educate consumers and manage repeat purchases, while specialty pet retailers and independent pet stores remain critical for trust-based discovery. At the same time, regulatory divergence across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa is pushing companies toward country-specific compliance playbooks rather than one-size-fits-all international expansion.
Artificial intelligence is becoming a practical differentiator in the CBD pet market by improving product development, customer education, supply chain control, and compliance monitoring. AI-enabled analytics can identify consumer search intent around CBD oil for dogs, hemp pet treats, calming chews, topical balms, and senior pet wellness, allowing brands to create evidence-aware content without crossing into prohibited drug claims. Machine learning can also support inventory planning for recurring-use products and optimize fulfillment across direct-to-consumer, marketplace, and specialty retail channels.
The cumulative impact is most visible in quality and risk management. AI tools can help screen certificates of analysis, flag inconsistent cannabinoid potency, detect contaminant trends, monitor adverse-event language in customer reviews, and identify labeling risks across jurisdictions. For responsible industry leaders, AI should augment-not replace-veterinary expertise, regulatory review, and laboratory verification.
North America remains the most commercially developed region for CBD pet products, led by the United States and supported by Canada's federally regulated cannabis framework. U.S. demand benefits from high pet ownership, established e-commerce infrastructure, and broad consumer familiarity with hemp-derived wellness products, although FDA restrictions on CBD in animal products continue to limit permissible claims. Canada offers a clearer national cannabis regime, but veterinary access and product authorization pathways remain tightly controlled.
Europe is characterized by strong consumer interest in pet wellness but complex regulatory fragmentation. The European Union treats CBD in many ingestible contexts through Novel Food considerations, while individual countries apply different controls to cannabinoids, THC thresholds, veterinary products, and marketing language. Asia-Pacific is promising over the long term because of rising pet humanization in China, Japan, South Korea, Australia, and India, yet cannabinoid regulations are often restrictive and require cautious market entry. Latin America shows emerging opportunity in Brazil and Mexico as cannabis policy evolves, while the Middle East and Africa remain selective markets where legal status, import controls, veterinary product rules, and cultural attitudes toward cannabis-derived ingredients strongly influence commercialization.
Within ASEAN, CBD pet commercialization is still limited by strict narcotics laws in several member states and uneven acceptance of cannabis-derived consumer products, making compliant importation, THC controls, and consumer education essential. The GCC is even more conservative; companies evaluating Gulf markets must prioritize legal due diligence, customs rules, veterinary product restrictions, and zero-tolerance approaches in some jurisdictions before considering pet CBD products.
The European Union offers scale but demands rigorous regulatory assessment, especially around Novel Food status, THC limits, and member-state enforcement practices. BRICS markets are highly diverse: China and India provide large pet population potential but tight cannabis controls, Brazil is gradually becoming more relevant as medical cannabis regulation matures, Russia remains constrained, and South Africa provides comparatively more visible cannabis policy discussion. G7 countries collectively represent advanced pet care spending, strong e-commerce adoption, and higher expectations for product safety, traceability, and substantiated labeling. NATO membership does not create a CBD regulatory framework, but many NATO economies overlap with developed pet care markets where compliance, batch documentation, and conservative claims are decisive.
The United States is the central demand engine for CBD pet products, but companies must operate with awareness that FDA has not approved CBD as an animal feed additive or pet supplement ingredient. Canada's regulated cannabis system creates a structured environment, while Mexico and Brazil represent longer-term Latin American opportunities as cannabis policy and veterinary wellness channels mature. In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong premium pet care demand, but CBD pet brands must navigate Novel Food rules, veterinary medicine classifications, national THC limits, and country-specific advertising standards. Russia presents higher regulatory and geopolitical complexity.
In Asia-Pacific, China and India have major pet population potential but restrictive cannabinoid pathways, making near-term opportunities more limited for ingestible CBD pet products. Japan and South Korea require careful attention to THC controls and import standards, while Australia combines high pet spending with a more medicalized cannabis framework that constrains over-the-counter CBD pet positioning. Across all countries, the most defensible approach is localized compliance, third-party testing, transparent hemp sourcing, adverse-event monitoring, and claims focused on general wellness rather than disease treatment.
Industry leaders should build trust before scale. The strongest CBD pet brands will invest in third-party laboratory testing, batch-specific certificates of analysis, THC and contaminant controls, transparent hemp sourcing, and clear serving guidance by animal size. Marketing should avoid disease-treatment claims and instead emphasize responsible pet wellness positioning supported by quality documentation and veterinary review.
Companies should also create region-specific regulatory playbooks, maintain adverse-event monitoring, and use AI-enabled compliance tools to review labeling, website copy, customer reviews, and marketplace listings. Partnerships with veterinarians, specialty pet retailers, and reputable contract manufacturers can improve credibility, while subscription programs and education-led content can strengthen retention in CBD oil, chews, treats, and topical pet products.
This executive summary is based on a structured review of established regulatory facts, publicly available government guidance, recognized cannabis policy frameworks, pet care industry dynamics, and observable commercial practices in hemp-derived pet wellness. Core references include the U.S. 2018 Farm Bill framework for hemp, the FDA's position that CBD is not approved for animal food or pet supplements, Canada's federal cannabis regulatory structure, and the European Union's Novel Food approach to CBD.
The analysis triangulates regional regulation, pet ownership and premiumization trends, retail channel behavior, consumer search demand, veterinary oversight considerations, and product quality requirements. Insights are presented conservatively to avoid unverified medical claims, market sizing, market share, or forecasting, and to reflect the compliance-sensitive nature of the CBD pet market.
The CBD pet market has durable long-term potential, but category development depends on trust, regulatory discipline, and product quality rather than aggressive claims. Pet owners are interested in hemp-derived wellness solutions, especially for dogs and aging companion animals, but regulators continue to scrutinize CBD use in ingestible animal products.
Brands that combine compliant marketing, verified testing, transparent sourcing, AI-supported risk management, and veterinarian-informed education will be best positioned to compete as the category matures across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.